Company Registration No. 02925647 (England and Wales)
KRUGER TISSUE GROUP (UK) LIMITED
FINANCIAL STATEMENTS
FOR THE YEAR ENDED
31 DECEMBER 2023
31 December 2023
PAGES FOR FILING WITH REGISTRAR
PM+M Solutions for Business LLP
Chartered Accountants
New Century House
Greenbank Technology Park
Challenge Way
Blackburn
Lancashire
BB1 5QB
KRUGER TISSUE GROUP (UK) LIMITED
BALANCE SHEET
AS AT
31 DECEMBER 2023
31 December 2023
- 1 -
2023
2022
Notes
£'000
£'000
£'000
£'000
Current assets
Debtors
5
-
0
2,211
Creditors: amounts falling due within one year
6
-
0
(1,313)
Net current assets
-
0
898
Capital and reserves
Called up share capital
7
33,447
33,447
Share premium account
58,126
19,922
Profit and loss reserves
(91,573)
(52,471)
Total equity
-
0
898

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The director of the company has elected not to include a copy of the profit and loss account within the financial statements.true

The financial statements were approved by the board of directors and authorised for issue on 15 July 2025 and are signed on its behalf by:
Mr D Angel
Director
Company registration number 02925647 (England and Wales)
KRUGER TISSUE GROUP (UK) LIMITED
STATEMENT OF CHANGES IN EQUITY
FOR THE YEAR ENDED 31 DECEMBER 2023
- 2 -
Share capital
Share premium account
Profit and loss reserves
Total
£'000
£'000
£'000
£'000
Balance at 1 January 2022
33,447
19,922
(52,471)
898
Year ended 31 December 2022:
Profit and total comprehensive income
-
-
-
0
-
0
Balance at 31 December 2022
33,447
19,922
(52,471)
898
Year ended 31 December 2023:
Loss and total comprehensive income
-
-
(39,102)
(39,102)
Issue of share capital
7
-
0
38,204
-
38,204
Balance at 31 December 2023
33,447
58,126
(91,573)
-
0
KRUGER TISSUE GROUP (UK) LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2023
- 3 -
1
Accounting policies
Company information

Kruger Tissue Group (UK) Limited is a private company limited by shares incorporated in England and Wales. The registered office is No. 1 St Paul's Square, Liverpool, Merseyside, L3 9SJ.

1.1
Accounting convention

These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime. The disclosure requirements of section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £'000.

The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.

These financial statements for the year ended 31 December 2023 are the first financial statements of Kruger Tissue Group (UK) Limited prepared in accordance with FRS 102, The Financial Reporting Standard applicable in the UK and Republic of Ireland. The date of transition to FRS 102 was 1 January 2022. The reported financial position and financial performance for the previous period are not affected by the transition to FRS 102.

The company has taken advantage of the exemption under section 399 of the Companies Act 2006 not to prepare consolidated accounts, on the basis that the group of which this is the parent qualifies as a small group. The financial statements present information about the company as an individual entity and not about its group.

1.2
Going concern

The financial statements have been prepared on a basis other than going concern on the grounds that the trading activities of the company have ceased and all future plans for the company are uncertain. As a result the company is no longer considered a going concern. Adjustments were made in a prior year financial statements to reduce assets to their realisable values and to reclassify fixed assets and long term liabilities as current assets and liabilities. Assets and liabilities continue to be recognised on this basis. Therefore, no restatement has been made of comparative figures. During the year to 31 December 2023 the company was non trading.

1.3
Fixed asset investments

Interests in subsidiaries, associates and jointly controlled entities are initially measured at cost and subsequently measured at cost less any accumulated impairment losses. The investments are assessed for impairment at each reporting date and any impairment losses or reversals of impairment losses are recognised immediately in profit or loss.

A subsidiary is an entity controlled by the company. Control is the power to govern the financial and operating policies of the entity so as to obtain benefits from its activities.

KRUGER TISSUE GROUP (UK) LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2023
1
Accounting policies
(Continued)
- 4 -
1.4
Financial instruments

The company has elected to apply the provisions of Section 11 ‘Basic Financial Instruments’ and Section 12 ‘Other Financial Instruments Issues’ of FRS 102 to all of its financial instruments.

 

Financial instruments are recognised in the company's balance sheet when the company becomes party to the contractual provisions of the instrument.

 

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

Basic financial assets

Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.

Classification of financial liabilities

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities.

Basic financial liabilities

Basic financial liabilities, including creditors, bank loans, loans from fellow group companies and preference shares that are classified as debt, are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.

 

Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.

 

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.

Changes in the fair value of derivatives that are designated and qualify as fair value hedges are recognised in profit or loss immediately, together with any changes in the fair value of the hedged asset or liability that are attributable to the hedged risk.

2
Employees

The average monthly number of persons (including directors) employed by the company during the year was:

2023
2022
Number
Number
Total
1
1
KRUGER TISSUE GROUP (UK) LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2023
- 5 -
3
Fixed asset investments
2023
2022
£'000
£'000
-
0
-
0
Movements in fixed asset investments
Shares in group companies
£'000
Cost or valuation
At 1 January 2023
-
Additions
39,095
At 31 December 2023
39,095
Impairment
At 1 January 2023
-
Impairment losses
39,095
At 31 December 2023
39,095
Carrying amount
At 31 December 2023
-
At 31 December 2022
-
4
Subsidiaries

Details of the company's subsidiaries at 31 December 2023 are as follows:

Name of undertaking
Registered office
Class of
% Held
shares held
Direct
Indirect
Kruger Tissue (Consumer) Limited
England and Wales
Ordinary
100.00
-
F.H.Lee LTD
England and Wales
Ordinary
0
100.00
Charles Turner & Company Limited
England and Wales
Ordinary
0
100.00
Kruger Tissue (Industrial) Limited
England and Wales
Ordinary
0
100.00
The aggregate capital and reserves and the result for the year of the subsidiaries noted above was as follows:
Name of undertaking
Capital and Reserves
Profit/(Loss)
£'000
£'000
F.H.Lee LTD
-
0
(8,611)
0
Charles Turner & Company Limited
-
0
(47,706)
0
Kruger Tissue (Industrial) Limited
(210)
0
(97)
0
KRUGER TISSUE GROUP (UK) LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2023
4
Subsidiaries
(Continued)
- 6 -

F.H.Lee LTD has a 31 March year end. The company does not trade but there were transaction in the year due to the reconstruction.

 

Kruger Tissue (Consumer) Limited had no profit or loss in the period and no capital and reserves at the year end.

5
Debtors
2023
2022
Amounts falling due within one year:
£'000
£'000
Amounts owed by group undertakings
-
0
2,204
Other debtors
-
0
7
-
0
2,211

Amounts due from group undertakings £nil (2022 - £2,204,000) are interest free and repayable on demand.

6
Creditors: amounts falling due within one year
2023
2022
£'000
£'000
Amounts owed to group undertakings
-
0
1,313

Amounts due to group undertakings £nil (2022 - £1,313,000) are interest free and repayable on demand.

7
Called up share capital
2023
2022
2023
2022
Ordinary share capital
Number
Number
£'000
£'000
Authorised
Ordinary shares of £1 each
40,000,000
40,000,000
40,000
40,000
Issued and fully paid
Ordinary shares of £1 each
33,446,791
33,446,790
33,447
33,447
8
Audit report information

As the income statement has been omitted from the filing copy of the financial statements, the following information in relation to the audit report on the statutory financial statements is provided in accordance with s444(5B) of the Companies Act 2006.

The auditor's report is unqualified and includes the following:

KRUGER TISSUE GROUP (UK) LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2023
8
Audit report information
(Continued)
- 7 -
Opinion

In our opinion the financial statements:

Emphasis of matter

We draw attention to note 1.2 of the financial statements, which describes the director's reasons why the financial statements have been prepared on a basis other than going concern. Our opinion is not modified in this respect.

Senior Statutory Auditor:
Daniel Bowles BFP ACA FCCA
Statutory Auditor:
PM+M Solutions for Business LLP
Date of audit report:
16 July 2025
9
Parent company

The immediate controlling party is Disley Holdings (UK). The ultimate parent undertaking and controlling party is Kruger Inc, a company registered in Canada. Kruger Inc is the parent undertaking of the largest and smallest group of undertakings to consolidate these financial statements at 31 December 2023. The consolidated financial statements of Kruger Inc are available from the secretary, Kruger Inc, Bedford Road, Montreal, Canada.

 

2023-12-312023-01-01falsefalsefalse16 July 2025CCH SoftwareCCH Accounts Production 2025.100No description of principal activityMr M GosselinMr D Angel029256472023-01-012023-12-31029256472023-12-31029256472022-12-3102925647core:CurrentFinancialInstrumentscore:WithinOneYear2023-12-3102925647core:CurrentFinancialInstrumentscore:WithinOneYear2022-12-3102925647core:ShareCapital2023-12-3102925647core:ShareCapital2022-12-3102925647core:SharePremium2023-12-3102925647core:SharePremium2022-12-3102925647core:RetainedEarningsAccumulatedLosses2023-12-3102925647core:RetainedEarningsAccumulatedLosses2022-12-3102925647core:ShareCapital2021-12-3102925647core:SharePremium2021-12-3102925647core:RetainedEarningsAccumulatedLosses2021-12-3102925647core:ShareCapitalOrdinaryShareClass12023-12-3102925647core:ShareCapitalOrdinaryShareClass12022-12-3102925647bus:Director22023-01-012023-12-3102925647core:RetainedEarningsAccumulatedLosses2022-01-012022-12-31029256472022-01-012022-12-3102925647core:RetainedEarningsAccumulatedLosses2023-01-012023-12-3102925647core:ShareCapital2023-01-012023-12-3102925647core:SharePremium2023-01-012023-12-3102925647core:Subsidiary12023-01-012023-12-3102925647core:Subsidiary22023-01-012023-12-3102925647core:Subsidiary32023-01-012023-12-3102925647core:Subsidiary42023-01-012023-12-3102925647core:Subsidiary112023-01-012023-12-3102925647core:Subsidiary222023-01-012023-12-3102925647core:Subsidiary332023-01-012023-12-3102925647core:Subsidiary442023-01-012023-12-3102925647core:Subsidiary22023-12-3102925647core:Subsidiary32023-12-3102925647core:Subsidiary42023-12-3102925647core:CurrentFinancialInstruments2022-12-3102925647core:WithinOneYear2023-12-3102925647core:WithinOneYear2022-12-3102925647core:CurrentFinancialInstruments2023-12-3102925647bus:OrdinaryShareClass12023-12-3102925647bus:OrdinaryShareClass12022-12-3102925647bus:PrivateLimitedCompanyLtd2023-01-012023-12-3102925647bus:SmallCompaniesRegimeForAccounts2023-01-012023-12-3102925647bus:FRS1022023-01-012023-12-3102925647bus:Audited2023-01-012023-12-3102925647bus:Director12023-01-012023-12-3102925647bus:FullAccounts2023-01-012023-12-31xbrli:purexbrli:sharesiso4217:GBP